Peptide Synthesis Market size was valued at USD 4,372.6 million in 2021 and is poised to grow at a significant CAGR of 7.7% over 2022–2028. The concept of individualized therapy with the best response and largest safety margin to assure improved patient care has driven interest in personalized treatment. Proteomic analysis is a strong and appealing method for determining the molecular profiles of various tissues, whether healthy or sick. The next step in customized medicine is personalized proteomics, also known as proteome profiling, which clarifies illness path mechanisms. Furthermore, Label-free sensors based on nanomaterials will then detect and quantify the ligand-receptor complexes. The technology will allow for the automated injection of the various reagents required for ligand synthesis, personalized and controlled peptide synthesis, and the use of proteomics in personalized medicine. The rising need for sophisticated treatments with few side effects and the increasing prevalence of diseases like cancer and cardiovascular disease drive more investment in customized therapy. Personalized medicine has the potential to improve healthcare while reducing costs. Players in the peptide synthesis market will benefit from such advancements in personalized medicine. Using peptides in the pharmaceutical and consumer healthcare industries is driving the market’s expansion. The peptides have many uses in treating malignancies, diabetes, and obesity, among other lifestyle problems. The rising prevalence of these metabolic and lifestyle diseases is opening the path for peptide therapies to be used in oncology and metabolic illnesses. According to a report published by the International Diabetes Federation in 2020, around 463 million individuals were living with diabetes in 2019, with the prevalence expected to reach 700 million by 2045. The key reason driving the need for Custom Peptide Synthesis Services is increased research and development by biotechnology and pharmaceutical businesses. The lack of time available to scientists and researchers to create their customized peptides may drive the Custom Peptide Synthesis Services market forward. Major peptide synthesis market companies may partner with smaller players to grow their market presence and raise revenue shares.
Recent Market Developments:
In August 2021, Bachem Holding AG (Switzerland) and Novo Nordisk (Denmark)collaborated to develop a greener technology for solid-phase peptide synthesis (SPPS), under which two studies were conducted to find solvent alternatives to replace the reprotoxic N, N-dimethylformamide (DMF), dichloromethane (DCM), and N-methyl-2-pyrrolidone (NMP).